Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

FORM 8.1(a) & (b) (Opening Position Disclosure)

prnewswire.com

DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS):

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE

1. KEY INFORMATION

(a)

Full name of discloser:

Alkermes plc

(b)

Owner or controller of interests and short

positions disclosed, if different from 1(a):

The naming of nominee or vehicle

companies is insufficient. For a trust, the

trustee(s), settlor and beneficiaries must

be named.

N/A

(c)

Name of offeror/offeree in relation to whose

relevant securities this form relates:

Use a separate form for each offeror/offeree

Avadel

Pharmaceuticals

plc

(d)

Is the discloser the offeror or the offeree?

OFFEROR

(e)

Date position held:

The latest practicable date prior to the

disclosure

3 November

2025

(f)

In addition to the company in 1(c) above, is

the discloser also making disclosures in

respect of any other party to the offer?

If it is a cash offer or possible cash offer, state

"N/A"

N/A

2. INTERESTS AND SHORT POSITIONS

If there are interests and positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates (Note 1)

N/A

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3. INTERESTS AND SHORT POSITIONS OF PERSONS ACTING

IN CONCERT WITH THE PARTY MAKING THE DISCLOSURE

Details of any interests and short positions (including directors'

and other employee options) of any person acting in concert with

the party making the disclosure:

Interests of J.P. Morgan (together with its members of staff under Rule

3.3(b)(v) of Part A of the Irish Takeover Rules), financial advisors to

Alkermes plc, but, for clarity, not held on behalf of Alkermes plc:

Party

Class of

Relevant

Security

Number of

ordinary

shares held

at midnight

(ET) on

3 November

2025

Percentage

of total

issued share

capital

(rounded)

55I, LLC

Ordinary

shares of

US$0.01

each

53

0.0001 %

JPMorgan

Chase Bank,

National

Association

Ordinary

shares of

US$0.01

each

13,500

0.0139 %

TOTAL

13,553

0.0139 %

Details of any open stock-settled derivative positions (including traded

options), or agreements to purchase or sell relevant securities, should

be given on a Supplemental Form 8.

Ap11

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement

or understanding, formal or informal, relating to relevant securities

which may be an inducement to deal or refrain from dealing entered

into by the party to the offer making the disclosure or any person

acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If

there are no such agreements, arrangements or understandings, state

"none"

None

(b) Agreements, arrangements or understandings

relating to options or derivatives

Full details of any agreement, arrangement or understanding

between the person disclosing and any other person relating to the

voting rights of any relevant securities under any option referred

to on this form or relating to the voting rights or future acquisition

or disposal of any relevant securities to which any derivative

referred to on this form is referenced. If none, this should be stated.

None

(c) Attachments

Is a Supplemental Form 8 attached?

YES/NO

No

Date of disclosure:

5 November 2025

Contact name:

Sandy Coombs, Alkermes

Telephone number:

+1 781 609 6377

Public disclosures under Rule 8.1 of the Rules must be made to a

Regulatory Information Service.

Ap12

NOTES ON FORM 8.1(a) and (b)

SOURCE Alkermes plc